Kapur S, Zipursky R B, Jones C, Remington G J, Wilson A A, DaSilva J, Houle S
Schizophrenia Division, Clarke Institute of Psychiatry, Toronto, ON, Canada.
Neuropsychopharmacology. 1996 Dec;15(6):562-6. doi: 10.1016/S0893-133X(96)00100-5.
Positron emission tomography (PET) studies of typical neuroleptics suggest that 60% to 80% of striatal D2 occupancy may be sufficient for optimal clinical treatment of psychosis. Therefore, striatal D2 occupancy may be used as an index to determine the optimal dose range. Toward this end, we determined the in vivo D2 profile of loxapine, using [11C]-raclopride and PET. Seven patients selected from a clinical population were scanned while taking steady-state oral loxapine from 10 to 100 mg/day. Their D2 receptor occupancy was estimated by comparing them to age-matched data from neuroleptic-naive patients. The D2 receptor occupancy ranged from 52% to 90%, and there was a very strong relationship between dose and D2 occupancy, suggesting that 15 to 30 mg/day of loxapine would produce, the putatively optimal, 60% to 80% striatal D2 blockade. This dose range is much lower than that used in most clinical settings and points to the potential efficacy of loxapine at lower doses.
对典型抗精神病药物的正电子发射断层扫描(PET)研究表明,纹状体D2受体占有率达到60%至80%可能足以实现精神病的最佳临床治疗。因此,纹状体D2受体占有率可作为确定最佳剂量范围的指标。为此,我们使用[11C] - 雷氯必利和PET测定了洛沙平的体内D2受体分布情况。从临床患者中选取了7名患者,在他们服用每天10至100毫克稳态口服洛沙平期间进行扫描。通过将他们与未服用过抗精神病药物的年龄匹配患者的数据进行比较,估算他们的D2受体占有率。D2受体占有率在52%至90%之间,剂量与D2受体占有率之间存在非常强的相关性,这表明每天15至30毫克的洛沙平会产生假定的最佳效果,即60%至80%的纹状体D2受体阻断。这个剂量范围远低于大多数临床环境中使用的剂量,表明洛沙平在较低剂量下可能具有疗效。